Company intelligence / Profile preview

Applied DNA Sciences, Inc.

Stony Brook, New York, United Statesadnas.com ↗

Ownership: Public · APDN
Development stage: Commercial

Overview

Applied DNA Sciences' customer ÚHKT has initiated a Phase I clinical trial for a CD123-specific autologous CAR T-cell therapy using the company's Linea DNA technology for the treatment of relapsed/refractory acute myeloid leukemia. The company also has other customers expected to initiate clinical trials in 2025.

Therapeutic areas: Oncology
Modalities: DNA-based therapeuticsRNA-based therapeuticsCAR T-cell therapiesNucleic acid-based therapeutics
Industry: Molecular Diagnostics

Partnerships

ÚHKT (Institute of Hematology and Blood Transfusion)Top-20 pharmaceutical manufacturer

Financials

Market cap: $7.3M
Total revenue: $605.3K
Enterprise value: $3.5M

Beyond the preview

Go deeper on Applied DNA Sciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Applied DNA Sciences, Inc..

Explore the full profile